
FDA approved ADC improves breast cancer survival by 37%
The US Food and Drug Administration (FDA) has approved datopotamab deruxtecan-dlnk (Datroway) a Trop-2-directed antibody and topoisomerase inhibitor conjugate, as a treatment for breast cancer. The decision was based on the results of the Phase III TROPION-Breast01 trial which showed a 37% reduction in the risk of disease progression or… Read More











